PCV104 ANALYSIS OF ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS IN THE US MEDICAID PROGRAM FROM 1991 TO 2007  by Bian, B et al.
A160 Abstracts
PCV101
A REVIEW OF TREATMENT PATTERNS OF PATIENTS WITH
PULMONARY ARTERIAL HYPERTENSION IN THREE EUROPEAN
COUNTRIES
Angalakuditi M1, Wright D2, Gaskin M3, Farkhoury W3
1Eli Lilly and Company, Indianapolis, IN, USA, 2IMS Health, London, UK, 3IMS Health, London, 
London, UK
OBJECTIVES: The aim of this study was to review the existing treatment patterns 
for patients diagnosed with pulmonary arterial hypertension in the UK, France and 
Germany. METHODS: IMS Disease Analyzer, a longitudinal patient database pro-
viding information from continuing physician-patient interaction on consultations, 
diagnoses and treatment within Primary Care, was used to review the treatment 
patterns for PAH patients in the UK, France and Germany over a two year period,
in order to describe: 1) different therapies used; 2) combination therapies; 3) clinical
and economic outcomes of different therapies; 4) dose and drug utilization patterns; 
and 5) resource utilization. RESULTS: In all three countries, the prevalence of 
PAH was found to increase with age, with two-thirds of PAH patients being 60 
years of age or older, with more female than male patients being diagnosed with PAH.
PAH patients were also found to have been prescribed at least one medication, with 
23% in France, 15% in Germany and 56% of patients in the UK being prescribed 
between 3 and 6 medications. In the UK, most prescriptions were found to refer to
diuretics, calcium channel blockers and anti-thrombotic agents. In France, most
prescriptions referred to beta-blockers, angiotensin receptor blockers and diuretics. In
Germany, most prescriptions referred to diuretics, calcium channel blockers and
beta blockers. For PAH patients in both France and Germany the median number of 
days receiving therapy over the 2 year period was found to be 100 days, whereas in
the UK, this ﬁ gure rose to 500 days. CONCLUSIONS: Whilst there were many simi-
larities in the sociodemographic proﬁ le of PAH patients, many differences in the
treatment patterns for patients diagnosed with PAH in the UK, France, and Germany 
were found.
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INFLUENCE OF COPAYMENT DIFFERENTIAL BETWEEN GENERIC AND 
PREFERRED BRAND PRESCRIPTIONS DRUGS ON GENERIC FILL RATE
Yuan Y1, Carlson AM2, Gleason PP3, Schommer JC4
1IMS Health, Blue Bell, PA, USA, 2Data Intelligence Consultants LLC, Eden Prairie, MN, USA, 
3Prime Therapeutics LLC, Eagan, MN, USA, 4University of Minnesota, Minneapolis, MN, USA
OBJECTIVES: To investigate the inﬂ uence of member copayment differential 
between generic and preferred brand name prescription drugs on generic ﬁ ll rate
(GFR) within two drug therapy classes (antidepressants and antihypertensive).
METHODS: This study was a retrospective observational cohort study using
individual member as the unit of analysis. The antidepressant cohort was members
who utilized an antidepressant (SSRI or SNRI). The antihypertensive cohort was 
members who had an antihypertensive claim (ACEI, ARBs, CCB, BB, and diuretics).
All 2006 claims were analyzed and adjusted to 30-day equivalents. A total of 149,359
members with age q22 years, continuously enrolled, no beneﬁ t change, with a 
ﬂ at copayment commercial beneﬁ t plan, and had at least one claim were eligible 
for analysis. Medical claims were used to calculate Charlson severity of illness
scores. A Tobit model to assess the inﬂ uence of independent variables: copayment 
differentials, age, gender, income, generic copayment, number of unique medications
taken, mail-order service use, specialty drug use, other maintenance drug use, Charlson 
score, on the GFR (dependent variable) was built for each cohort. RESULTS:
Of 149,359 members, the antidepressant cohort comprised 22,484 (15.1%) members 
with an average 5.7 30-day antidepressant claims, mean $16.40 copayment
differential, and GFR of 51.8%. For the antihypertensive cohort 33,673 (22.5%) 
members had 8.6 antihypertensive 30-day claims, mean $16.50 copayment differen-
tial, and GFR of 72.3%. Antidepressant Tobit model found the mean marginal 
effect of copayment differential on GFR was 0.005 (p  0.001) indicating a $10 
copayment differential increase is estimated to increase antidepressant GFR by
5% points. In the antihypertensive cohort, the mean marginal effect of copayment 
differential on GFR was 0.001 (p  0.001). When copayment differential increased 
by $10 the estimated GFR increased by 1% point. CONCLUSIONS: There was
a signiﬁ cant positive relationship between copayment differential and generic ﬁ ll
rate. However, the magnitude of the effect varied across different drug therapy
classes.
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ASSOCIATION BETWEEN COPAYMENT AND ADHERENCE TO STATIN 
TREATMENT IN A VETERAN POPULATION: A RETROSPECTIVE
ANALYSIS
Bounthavong M1, Kazerooni R1, Christopher MLD1, Mendes M1, Juzba M2, Plowman BK1, 
Morreale AP1
1Veterans Affairs San Diego Healthcare System (VASDHS), San Diego, CA, USA, 
2Department of Veterans Affairs (Long Beach), Long Beach, CA, USA
OBJECTIVES: This study investigated the association between copayment and
adherence to statin treatment in a veteran population at the Veterans Affairs San 
Diego Healthcare System (VASDHS). METHODS: This was a retrospective analysis
of patients initiated on statin therapy and followed for 12 months to determine 
adherence. Patients who began a statin during the period of November 2006 to 
December 2007 were included. Patients who switched statin therapy or who were 
discontinued before 12 months were excluded. Eligibility was established if patients
had at least two visits to their provider post-index date and one visit pre-index
date. Adherence was deﬁ ned as a medication possession ratio (MPR) q80%. Indepen-
dent variables included: age, gender, ethnicity, BMI, number of medications, baseline 
lipid panel, percent service connection, and comorbid conditions. Service connection 
deﬁ nes level of medical and prescription coverage beneﬁ t and awarded based on
disability, socioeconomic and military-service factors. Non-parametric continuous 
data was evaluated using the Mann Whitney-U. Categorical data was evaluated
using the Pearson Chi-squared test. Logistic regression model was used to determine 
predictors of adherence. RESULTS: A majority of the cohort (N  6890) was 
63.7 (o11.23) years old, male (95.6%), Caucasian (19.4%), taking simvastatin 
(84.6%), and had hypertension (73.0%). Statistically signiﬁ cant differences were 
seen in all variables between the adherent and nonadherent groups at baseline 
with few exceptions. Nonadherent patients had an MPR of 55% compared to adher-
ent patients MPR of 95% (p  0.0005). No difference in adherence found between
non-service connected patients and those service connected (p  0.449). Patients 
who were older (OR  1.01, 95%CI: 1.002–1.014), had higher percent service
connection (OR  1.00, 95%CI: 1.000–1.004), and high quantity of medications
(OR  1.05, 95%CI: 1.032–1.064) were more likely to be adherent. CONCLUSIONS:
Copayment had no affect on adherence. However, patients who had a higher 
percentage service connection were more likely to be adherent to their statin
medication.
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OBJECTIVES: Angiotensin-converting-enzyme (ACE) inhibitors have been widely 
used for treatment of hypertension, heart failure, diabetes mellitus and kidney disease. 
The purposes of this study was to describe the utilization and spending trends of ACE 
inhibitors and assess market-share competition between brand-name and generic drugs 
in the US Medicaid Program. METHODS: Since captopril, the 1st ACE inhibitor, 
introduced in 1981, there are 22 brand-names including 10 combination drugs are 
available in the market. Multiple generic ACE inhibitors are available including
benazepril, captopril, enalapril, fosinpril, lisinopril, moexipril, perindopril, quinapril, 
and ramipril. National Medicaid pharmacy data were extracted from CMS from 1st
quarter 1991 to 3rd quarter 2007 in order to obtain quarterly total prescription
numbers and reimbursement amounts. The per-prescription reimbursement as a proxy 
of drug price was calculated for all study ACE inhibitors. The market-shares were 
calculated based on proportion of total prescriptions numbers. RESULTS: By 2005,
the expenditure for ACE inhibitors reached to $490.5 million ($248 million for brand 
drugs and $242.5 million generic drugs). But It had been seen a sudden drop on the
utilization of both brand-name and generic ACEIs since 2006 quarter 1 because of 
implementation of Medicare PartD. The average per-prescription reimbursement for 
brand-name ACE inhibitors increased overtime from $35.2 in the ﬁ rst quarter of 1991 
to $67.1 in the third quarter of 2007, whereas per-prescription reimbursement for
generics decreased from $31.5 in 1996 to $22.4 in 2007. After the generics entry, the
market share of brand-name drugs dropped from 100% in 1991 to 12.6% in 2007.
CONCLUSIONS: Generic reimbursement prices decreased due to their competitions,
while the brand-name drug prices increased overtime regardless new entry counter-
parts. There is a dramatic competition in market share between brand-name and 
generic drugs in Medicaid program.
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IN PROMETHEUS’ SHADOW: EPIDEMIOLOGICAL AND ETHICAL
PERSPECTIVES ON OUTCOMES OF CARDIOPULMONARY
RESUSCITATION
Levy A1, Koning F2, Lockey R2, Bellack N3, Christie T4, Desjardins E2
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OBJECTIVES: Cardiopulmonary resuscitation (CPR), a life-saving technology devel-
oped mid-20th century, was intended to prevent sudden, unexpected death. Since then, 
CPR has increasingly been performed on terminal patients with irreversible illness
treated in acute care settings. The objectives were to: synthesize the literature estimates
of survival following CPR delivered in acute care hospitals; identify predictors of sur-
vival; and contextualize the ﬁ ndings in terms of ethics of end of life care. METHODS:
We conducted a comprehensive literature review using PUBMED to identify studies 
in which survival after CPR was reported for adult patients treated in hospitals.
RESULTS: The literature yielded 130 studies reporting survival after CPR. The most 
common outcomes were return of spontaneous circulation (52% of studies, arithmetic
mean survival 43% (range 12% to 100%)) and survival to hospital discharge (64%
of studies, arithmetic mean survival 15% (range 0% to 40%)). Diagnoses with lower 
rates of survival included metastatic cancer, sepsis, renal failure, pneumonia, stroke, 
diabetes and AIDS. CONCLUSIONS: While heterogeneity in study populations and
outcomes invalidated summary estimates, all studies showed that only a minority of 
patients undergoing CPR survived even to hospital discharge. Current use of CPR in
many hospitalized patients likely does not achieve consensus goals, to: preserve life, 
restore health, and limit disability. Reviving terminally ill patients or those with major 
co morbidities should involve consideration of the efﬁ cacy, preferences of patients and
caregivers, and burdens imposed. However, unlike Prometheus who was punished for
stealing ﬁ re from Zeus and handing it to mankind, the burden of CPR is carried by
